167 related articles for article (PubMed ID: 18265979)
1. Fas-mediated T cell deletion potentiates tumor antigen-specific tolerance in a mouse model of prostate cancer.
Tseng-Rogenski SS; Arredouani MS; Neeley YC; Lu B; Chinnaiyan AM; Sanda MG
Cancer Immunol Immunother; 2008 Sep; 57(9):1357-65. PubMed ID: 18265979
[TBL] [Abstract][Full Text] [Related]
2. Partially circumventing peripheral tolerance for oncogene-specific prostate cancer immunotherapy.
Neeley YC; Arredouani MS; Hollenbeck B; Eng MH; Rubin MA; Sanda MG
Prostate; 2008 May; 68(7):715-27. PubMed ID: 18302222
[TBL] [Abstract][Full Text] [Related]
3. Clonal deletion of simian virus 40 large T antigen-specific T cells in the transgenic adenocarcinoma of mouse prostate mice: an important role for clonal deletion in shaping the repertoire of T cells specific for antigens overexpressed in solid tumors.
Zheng X; Gao JX; Zhang H; Geiger TL; Liu Y; Zheng P
J Immunol; 2002 Nov; 169(9):4761-9. PubMed ID: 12391185
[TBL] [Abstract][Full Text] [Related]
4. Peripheral T cell tolerance occurs early during spontaneous prostate cancer development and can be rescued by dendritic cell immunization.
Degl'Innocenti E; Grioni M; Boni A; Camporeale A; Bertilaccio MT; Freschi M; Monno A; Arcelloni C; Greenberg NM; Bellone M
Eur J Immunol; 2005 Jan; 35(1):66-75. PubMed ID: 15597325
[TBL] [Abstract][Full Text] [Related]
5. Vaccination with mRNAs encoding tumor-associated antigens and granulocyte-macrophage colony-stimulating factor efficiently primes CTL responses, but is insufficient to overcome tolerance to a model tumor/self antigen.
Hess PR; Boczkowski D; Nair SK; Snyder D; Gilboa E
Cancer Immunol Immunother; 2006 Jun; 55(6):672-83. PubMed ID: 16133108
[TBL] [Abstract][Full Text] [Related]
6. Tolerance induction by veto CTLs in the TCR transgenic 2C mouse model. II. Deletion of effector cells by Fas-Fas ligand apoptosis.
Reich-Zeliger S; Gan J; Bachar-Lustig E; Reisner Y
J Immunol; 2004 Dec; 173(11):6660-6. PubMed ID: 15557157
[TBL] [Abstract][Full Text] [Related]
7. Fetal expression of Fas ligand is necessary and sufficient for induction of CD8 T cell tolerance to the fetal antigen H-Y during pregnancy.
Vacchio MS; Hodes RJ
J Immunol; 2005 Apr; 174(8):4657-61. PubMed ID: 15814689
[TBL] [Abstract][Full Text] [Related]
8. Origin of androgen-insensitive poorly differentiated tumors in the transgenic adenocarcinoma of mouse prostate model.
Huss WJ; Gray DR; Tavakoli K; Marmillion ME; Durham LE; Johnson MA; Greenberg NM; Smith GJ
Neoplasia; 2007 Nov; 9(11):938-50. PubMed ID: 18030362
[TBL] [Abstract][Full Text] [Related]
9. Characterization of the Fas ligand/Fas-dependent apoptosis of antiretroviral, class I MHC tetramer-defined, CD8+ CTL by in vivo retrovirus-infected cells.
Rich RF; Green WR
J Immunol; 2002 Mar; 168(6):2751-8. PubMed ID: 11884442
[TBL] [Abstract][Full Text] [Related]
10. Dendritic cells induce specific cytotoxic T lymphocytes against prostate cancer TRAMP-C2 cells loaded with freeze- thaw antigen and PEP-3 peptide.
Liu XQ; Jiang R; Li SQ; Wang J; Yi FP
Asian Pac J Cancer Prev; 2015; 16(2):571-8. PubMed ID: 25684489
[TBL] [Abstract][Full Text] [Related]
11. Antiretroviral cytolytic T-lymphocyte nonresponsiveness: FasL/Fas-mediated inhibition of CD4(+) and CD8(+) antiviral T cells by viral antigen-positive veto cells.
Rich RF; Green WR
J Virol; 1999 May; 73(5):3826-34. PubMed ID: 10196277
[TBL] [Abstract][Full Text] [Related]
12. Immunosensitization of melanoma tumor cells to non-MHC Fas-mediated killing by MART-1-specific CTL cultures.
Frost PJ; Butterfield LH; Dissette VB; Economou JS; Bonavida B
J Immunol; 2001 Mar; 166(5):3564-73. PubMed ID: 11207317
[TBL] [Abstract][Full Text] [Related]
13. FAS/FAS ligand interaction at the placental interface is not required for the success of allogeneic pregnancy in anti-paternal MHC preimmunized mice.
Chaouat G; Clark DA
Am J Reprod Immunol; 2001 Feb; 45(2):108-15. PubMed ID: 11216873
[TBL] [Abstract][Full Text] [Related]
14. Apoptosis defects analyzed in TcR transgenic and fas transgenic lpr mice.
Mountz JD; Zhou T; Bluethmann H; Wu J; Edwards CK
Int Rev Immunol; 1994; 11(4):321-42. PubMed ID: 7528763
[TBL] [Abstract][Full Text] [Related]
15. Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide inhibit T cell-mediated cytotoxicity by inhibiting Fas ligand expression.
Delgado M; Ganea D
J Immunol; 2000 Jul; 165(1):114-23. PubMed ID: 10861043
[TBL] [Abstract][Full Text] [Related]
16. Human cytotoxic T lymphocytes with reduced sensitivity to Fas-induced apoptosis.
Dotti G; Savoldo B; Pule M; Straathof KC; Biagi E; Yvon E; Vigouroux S; Brenner MK; Rooney CM
Blood; 2005 Jun; 105(12):4677-84. PubMed ID: 15713795
[TBL] [Abstract][Full Text] [Related]
17. Tumor-specific CTL kill murine renal cancer cells using both perforin and Fas ligand-mediated lysis in vitro, but cause tumor regression in vivo in the absence of perforin.
Seki N; Brooks AD; Carter CR; Back TC; Parsoneault EM; Smyth MJ; Wiltrout RH; Sayers TJ
J Immunol; 2002 Apr; 168(7):3484-92. PubMed ID: 11907109
[TBL] [Abstract][Full Text] [Related]
18. Induction of specific T cell tolerance by Fas ligand-expressing antigen-presenting cells.
Zhang HG; Su X; Liu D; Liu W; Yang P; Wang Z; Edwards CK; Bluethmann H; Mountz JD; Zhou T
J Immunol; 1999 Feb; 162(3):1423-30. PubMed ID: 9973398
[TBL] [Abstract][Full Text] [Related]
19. Control of advanced choroid plexus tumors in SV40 T antigen transgenic mice following priming of donor CD8(+) T lymphocytes by the endogenous tumor antigen.
Schell TD; Tevethia SS
J Immunol; 2001 Dec; 167(12):6947-56. PubMed ID: 11739514
[TBL] [Abstract][Full Text] [Related]
20. Activated cytotoxic lymphocytes promote tumor progression by increasing the ability of 3LL tumor cells to mediate MDSC chemoattraction via Fas signaling.
Yang F; Wei Y; Cai Z; Yu L; Jiang L; Zhang C; Yan H; Wang Q; Cao X; Liang T; Wang J
Cell Mol Immunol; 2015 Jan; 12(1):66-76. PubMed ID: 24769795
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
